JPM Highlights: What’s Next in ImmunoOncology - Triumvira Immunologics | Engineered T Cell Therapies
Episode Overview
In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases.
Dr. Robert Ross
Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s mission is to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Before becoming CEO, Rob served as Chief Medical Officer at Surface. Prior to joining Surface, he led several programs in hematology and oncology at Bluebird Bio, including the anti-BCMA CAR T cell therapy program. Rob received his MD from Columbia University and has received extensive training in hematology and oncology at top institutions including the University of California San Francisco, Dana Farber, and Mass General Hospital.
Dr. Paul Lammers
Dr. Paul Lammers is the Chief Executive Officer of Triumvira Immunologics. Triumvira is leveraging its proprietary T-cell antigen coupling technology to enhance engineered cell therapy to target solid tumors. Paul has a rich background in biotech management, having served as President & CEO at Mirna Therapeutics and Chief Medical Officer and Head of US Product Development for EMD Serono. Paul received his MD from Radboud University in the Netherlands.
Hosted by Joe Varriale.
[On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions](/content/on-the-backside-of-the-hype-cycle-cancer-cell-therapy-companies-grappling-with-lofty-expectations-and-challenging-market-conditions/ "On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions"/index.html)
[Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting](/content/triumvira-immunologics-to-present-new-data-on-its-tac-t-cell-autologous-and-allogeneic-products-and-the-ongoing-phase-i-ii-solid-tumor-trial-at-the-2023-aacr-annual-meeting/ "Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting"/index.html)